GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Meribank Biotech Co Ltd (ROCO:4724) » Definitions » Gross-Profit-to-Asset %

Meribank Biotech Co (ROCO:4724) Gross-Profit-to-Asset % : 17.30% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Meribank Biotech Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Meribank Biotech Co's annualized Gross Profit for the quarter that ended in Dec. 2023 was NT$158.6 Mil. Meribank Biotech Co's average Total Assets over the quarter that ended in Dec. 2023 was NT$916.7 Mil. Therefore, Meribank Biotech Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 17.30%.


Meribank Biotech Co Gross-Profit-to-Asset % Historical Data

The historical data trend for Meribank Biotech Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Meribank Biotech Co Gross-Profit-to-Asset % Chart

Meribank Biotech Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial 13.74 16.18 10.74 10.57 14.55

Meribank Biotech Co Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.99 9.38 11.95 14.73 17.30

Competitive Comparison of Meribank Biotech Co's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Meribank Biotech Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Meribank Biotech Co's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Meribank Biotech Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Meribank Biotech Co's Gross-Profit-to-Asset % falls into.



Meribank Biotech Co Gross-Profit-to-Asset % Calculation

Meribank Biotech Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=138.87/( (846.325+1062.008)/ 2 )
=138.87/954.1665
=14.55 %

Meribank Biotech Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=158.57/( (771.47+1062.008)/ 2 )
=158.57/916.739
=17.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Meribank Biotech Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Meribank Biotech Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Meribank Biotech Co (ROCO:4724) Business Description

Traded in Other Exchanges
N/A
Address
Sector 1, Neihu Road, 1st Floor, No.68, Neihu District, Taipei, TWN, 11493
Meribank Biotech Co Ltd is engaged in Research and development and sales of new cell drugs and also Umbilical cord blood, placenta and umbilical cord mesenchymal stem cells processing, testing and cryopreservation.

Meribank Biotech Co (ROCO:4724) Headlines

No Headlines